The future of cancer treatment is built on targeted and precise solutions.
n.c.a. (non-carrier-added) Lutetium-177 is the powerful technology behind this future.
When n.c.a. Lu-177 is paired with a cancer-seeking molecule, it offers a new level of precision against disease. Thanks to its radioactive properties, it targets cancer cells with high accuracy while causing minimal harm to healthy tissue. This makes treatments more effective, safer, and more patient-friendly.
The drug delivers the isotope directly to the cancer and its metastases through a smart carrier molecule. The isotope, in turn, emits short-range radiation to destroy only the cancer cells. This approach provides a more targeted and gentler solution in cancer treatment, making a difference on a global scale.
n.c.a. Lu-177 is produced in compliance with cGMP (current Good Manufacturing Practice) standards. It also meets, and even exceeds, all the requirements of the European Pharmacopoeia monographs for Lutetium.